A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Basit Öğe Kaydı
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorscopusidİrfan Çiçin / 8922379100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.authorwosidİrfan Çiçin / JQU-1347-2023
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorÖztürk, Akın
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÇiçin, İrfan
dc.date.accessioned2025-04-18T08:31:17Z
dc.date.available2025-04-18T08:31:17Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractTo evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.
dc.identifier.citationKilickap, S., Ozturk, A., Karadurmus, N., Korkmaz, T., Yumuk, P. F., Cicin, I., ... & Erman, M. (2024). A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy. Medicine, 103(21), e37972.
dc.identifier.doi10.1097/MD.0000000000037972
dc.identifier.endpage8
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue21
dc.identifier.pmid38787994
dc.identifier.scopus2-s2.0-85194219961
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1097/MD.0000000000037972
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6577
dc.identifier.volume103
dc.identifier.wosWOS:001230616700060
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKılıçkap, Saadettin
dc.institutionauthorÇiçin, İrfan
dc.institutionauthoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.institutionauthoridİrfan Çiçin / 0000-0002-7584-3868
dc.language.isoen
dc.publisherLippincott williams & wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectImaging Characteristics
dc.subjectGene REARRANGEMENT Rearrangement
dc.subjectAdenocarcinomas
dc.subjectManagementfusion
dc.titleA multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu